Kalbe Farma launched an IDR 500 billion buyback of Kalbe Farma stock

Published on 10/14/2026 at 13:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 14.04 percent to IDR 19.47 trillion. Kalbe Farma stock stood at EUR 0.04 on October 14, 2026, with Jakarta at IDR 780.

Buyback and earnings outlook

Kalbe Farma announced an IDR 500 billion buyback on September 16, 2026.
First-half 2026 revenue reached IDR 19.47 trillion, up 14.04 percent year on year.
Kalbe Farma stock was trading at EUR 0.04 at 1:31 p.m. CEST on October 14, 2026, at Lang & Schwarz.
Market capitalization stood at IDR 35.3 trillion on October 14, 2026.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ID1000125107) had announced an IDR 500 billion share buyback on September 16, 2026, using internal funds, according to Liputan6.com. The program runs from September 17 through December 17, 2026, while management expects the use of cash to reduce interest income by IDR 8.4 billion.

Three dated corporate signals

On August 1, 2026, Liputan6.com reported first-half revenue of IDR 19.47 trillion, up 14.04 percent from IDR 17.07 trillion in the same period of 2025. On September 16, 2026, the outlet reported the IDR 500 billion buyback plan. On September 28, 2026, Kontan said UBS Securities Indonesia analyst Permada Darmono viewed the buyback as a valuation signal.

What does the buyback change?

The capital action offers a direct trade-off. Kontan reported that the lower share count could lift earnings per share by 1.10 percent based on 2025 results, while the cash deployment would reduce interest income by IDR 8.4 billion. A separate company estimate cited by Investortrust.id put pro forma earnings per share at IDR 81.44, compared with IDR 80.51 for fiscal year 2025.

The operating picture is less uniform. First-half 2026 gross profit rose 4.45 percent to IDR 7.31 trillion, below the 14.04 percent revenue growth, while net income attributable to owners fell 2.80 percent to IDR 1.91 trillion, according to Liputan6.com. The gap between sales and profit growth makes margin control the central operating issue.

Next reporting date

Investing.com lists November 3, 2026 as Kalbe Farma's next earnings date. The buyback period is scheduled to end on December 17, 2026, according to Liputan6.com.

Stock price and valuation

Kalbe Farma stock was trading at EUR 0.04 at Lang & Schwarz on October 14, 2026 at 1:31 p.m. CEST. On the Jakarta Stock Exchange, the stock was last at IDR 780 on October 14, 2026, while market capitalization stood at IDR 35.3 trillion. The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.